



**BIORESTORATIVE THERAPIES TO PRESENT AT 7th INTERNATIONAL
CONFERENCE ON CELL THERAPY FOR CARDIOVASCULAR DISEASE**

***COMPANY TO DISCUSS THERMOSTEM™ PROGRAM ON METABOLIC DISORDERS
AND OBESITY***

JUPITER, FL, January 23, 2012 – BioRestorative Therapies, Inc. (OTCQB: BRTX) (“BRT”) today announced that it will be presenting at the Seventh International Conference on Cell Therapy for Cardiovascular Disease. The event, being held at the New York-Presbyterian Hospital/Columbia University Medical Center, is a two-and-a-half-day conference dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease.

Dr. Amit Patel, Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah and a member of the BRT Scientific Advisory Board, will be presenting his findings relating to brown fat stem cells and metabolic disorders (one of BRT’s stem cell initiatives). His talk, entitled “*Metabolic Syndrome: A Role For Cell Therapy,*” will be on Wednesday, January 25th at 1:50 PM.

Mark Weinreb, Chairman and CEO of BRT, has also been selected to serve on an industry panel and will discuss BRT’s *ThermoStem™ Program* and the use of brown fat stem cells as potential therapeutics. The session will be held on Thursday, January 26th from 3:15-4:15 PM.

BRT is involved in a research initiative focusing on the use of Brown Fat stem cells to potentially treat metabolic disorders and obesity that may lead to heart disease, diabetes, hypertension, kidney disease and other diseases and disorders.

The Conference will take place January 25-27 at the Vivien and Seymour Milstein Family Heart Center, Myrna L. Daniels Auditorium, NYPH/Columbia University Medical Center, 173 Fort Washington Avenue, First Floor, New York City.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc.'s goal is to become a medical center of excellence using cell and tissue protocols, primarily involving a patient's own (autologous) adult stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. In June 2011, the Company launched a technology that involves the use of a brown fat cell-based therapeutic/aesthetic program, known as the *ThermoStem™ Program*. The *ThermoStem™ Program* will focus on treatments for obesity, weight loss, diabetes, hypertension, other metabolic disorders and cardiac deficiencies and will involve the study of stem cells, several genes, proteins and/or mechanisms that are related to these diseases and disorders. As more and more cellular therapies become standard of care, the Company believes its strength will be its focus on the unity of medical and scientific explanations for clinical procedures and outcomes for future personal medical applications. The Company also plans to offer and sell facial creams and products under the Stem Pearls™ brand.

#####

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:

Mark Weinreb

CEO

Tel: (561) 904-6070

Fax: (561) 429-5684